Home › NCT06933381
Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
RecruitingHealthy volunteers welcome
Topical Vapocoolant to Reduce Pain With Nexplanon Insertion: A Randomized Controlled Trial
Who can join
Ages 14 and older · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * At least 14 years or older * Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402 * English speaking * Able and willing to sign the informed consent form and agree to terms of the study Exclusion Criteria: * Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure * Known previous exposure to vapocoolant spray * Nexplanon removal and reinsertion same day during visit in the same arm * Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane) * Unable to provide written, informed consent in English
About the study
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
What is being tested
- Vapocoolant spray (device)
- Placebo (other)
Sponsor: Queen's Medical Center · Participants: 70 · Started: Jun 16, 2025
Contact the study team
- Sarah Murayama, MD · Phone: 808-783-0298
- Mary Tschann, PhD · Phone: 808-375-3785
Official record on ClinicalTrials.gov — NCT06933381
Locations in the U.S.
| Hawaii | Queens Medical Center POB 2 Suite 402, Honolulu Queens Medical Center POB1 Clinic 1004, Honolulu Women's Center Queen's North Hawai'i Community Hospital Suite #124 and #120, Waimea (Not yet recruiting) |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.